Non-alcoholic fatty liver disease (
NAFLD), newly renamed metabolic dysfunction-associated
liver disease (MASLD), is a leading cause of
liver disease in children and adults. There is a paucity of data surrounding potential
biomarkers and therapeutic targets, especially in pediatric
NAFLD. Leukocyte cell-derived
chemotaxin 2 (LECT2) is a
chemokine associated with both
liver disease and skeletal muscle
insulin resistance. Our aim was to determine associations between LECT2 and common clinical findings of
NAFLD in pediatric patients.
Enzyme-linked
immunosorbent assay (ELISA) was used to measure serum LECT2 concentrations in children (aged 2-17 years) with and without
NAFLD. LECT2 concentrations were then correlated to clinical parameters in
NAFLD. Mean LECT2 was significantly elevated in children with
NAFLD versus healthy controls (n = 63 vs. 42, 5.83 ± 1.98 vs. 4.02 ± 2.02 ng/mL, p < 0.005). Additionally, LECT2 had strong correlations with body mass index (BMI) (Pearson r = 0.301, p = 0.002). A LECT2 concentration of 3.76 mg/mL predicts
NAFLD with a sensitivity of 90.5% and specificity of 54.8%. Principal component analysis and logistic regression models further confirmed associations between LECT2 and
NAFLD status. This study demonstrates increased serum LECT2 concentrations in pediatric
NAFLD, which correlates with BMI and shows strong predictive value within these patients. Our data indicate that LECT2 is a potential diagnostic
biomarker of disease and should be further investigated in pediatric as well as adult
NAFLD.